首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Blood Advances

Blood Advances杂志,由American Society of Hematology出版,于2016年创刊,24 issues/year,出版语言English,ISSN:2473-9529,E-ISSN:2473-9537。

投稿咨询
Blood Advances
Blood Advances
Blood Advances
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
7.7
CiteScore
11.8
期刊收录
SCI、SCIE

Blood Advances(中文译名:《血液进展》),ISSN:2473-9529,EISSN:2473-9537,是American Society of Hematology出版的国际性学术期刊,创刊于2016年,以24 issues/year形式稳定发行,2026年总发文量约494篇。该刊采用非OA开放访问,学科归属为Medicine - Hematology。该刊是医学、血液学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达7.7,2025年期刊CiteScore为11.8,2025年期刊自引率约3.9%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Blood Advances长期聚焦医学、血液学及相关产业的技术应用前沿,在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、血液学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Canada、GERMANY (FED REP GER)、France、Italy、Japan等为核心发文国家与地区;HARVARD UNIVERSITYUNIVERSITY OF TEXAS SYSTEM、DANA-FARBER CANCER INSTITUTE、UNIVERSITY OF PENNSYLVANIA、MEMORIAL SLOAN KETTERING CANCER CENTER、MAYO CLINIC、UNIVERSITY OF CALIFORNIA SYSTEM等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 13 / 103

87.9

学科:HEMATOLOGY SCIE Q1 11 / 103

89.81

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 12 / 97

88.1

学科:HEMATOLOGY SCIE Q1 12 / 97

88.14


中国学者近期发文

1
Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphom

Author:Qin, Yao; Xia, Pan-Hui; Huang, Yao-Hui; Cheng, Shu; Liu, Jia-Ying; Gao, Xiao; Cai, Ming-Ci; Wang, Cong; Qiu, Yu-Ran; Hu, Song; Shi, Qing; Yang, Hao-Xu; Zhao, Jia-Yi; Wang, Lan; Xiong, Jie; Zhao, Wei-Li

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 7, pp. 2125-2141. DOI: 10.1182/bloodadvances.2025017682

2
Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strateg

Author:Shen, Guomin; Song, Dan; Li, Shixin; Chen, Xuejie; Richter, Catherine E.; Dong, Shixia; Guo, Yiming; Liu, Hongli; Shen, Yan; Hao, Zhenyu; Stafford, Darrel W.; Shavit, Jordan A.; Cao, Qing; Tie, Jian-Ke

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 7, pp. 2363-2375. DOI:

3
Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysi

Author:Shen, Jing; Zhang, Jingyi; Zhu, Zhengyu; Ma, Haobo; Zhang, Junpeng; Zhou, Fan; Tian, Hua; Liu, JingHua

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 7, pp. 2495-2505. DOI: 10.1182/bloodadvances.2025018474

4
RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran

Author:Gabrielsen, Anders; Ueckert, Sebastian; Nilsson, Catarina; Egnell, Ann-Charlotte; Fu, Jing; Wikstrom, Johannes; Svedlund, Sara; Friend, Richard; Zhang, Hongyan; Liang, Zicai; Gao, Shan; Gan, Li-Ming

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 7, pp. 2541-2548. DOI: 10.1182/bloodadvances.2025018348

5
TNIK as a molecular switch regulating platelet function in hemostasis and hyperlipidemia-associated thrombosi

Author:Li, Li; Chen, Xiaoyan; Li, Jingke; Deng, Xin; Sheng, Yilin; Lu, Linrong; Hu, Hu

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 6, pp. 1864-1878. DOI: 10.1182/bloodadvances.2025017737

6
Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mic

Author:Yu, Hongyin; Schroeder, Jocelyn A.; Mattson, Jeremy G.; Gao, Chunyan; Shi, Qizhen

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 6, pp. 1883-1896. DOI: 10.1182/bloodadvances.2025017921

7
Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 tria

Author:Jin, Yuanyuan; Cheng, Xin; Zhang, Xuezhong; Shi, Qinglin; Zhu, Yu; Li, Jianyong; Fan, Lei; Chen, Lijuan

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 6, pp. 2016-2022. DOI: 10.1182/bloodadvances.2025018945

8
Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogrammin

Author:Carminita, Estelle; Camacho, Virginia; Branfield, Siobhan; Walsey, Ethan; Barrachina, Maria N.; Tabang, Dylan N.; Lee, Dong H.; Becker, Isabelle C.; V. Brodsky, Sergey; Issa, Samer M.; Gendron, Nicolas; Machado, Sarah; Wolberg, Alisa S.; Steen, Hanno; Kerlin, Bryce; Machlus, Kellie R.; Zarjou, Abolfazl; Italiano, Joseph E

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 5, pp. 1444-1456. DOI: 10.1182/bloodadvances.2025017625

9
Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphom

Author:Li, Na; Liu, Yicen; Zhang, Linna; Guo, Saisai; Wu, Zhihao; Xu, Yan; Yang, Ming; Kong, Jixia; Che, Yuxuan; Shao, Kun; Yang, Hong

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 5, pp. 1722-1732. DOI: 10.1182/bloodadvances.2025016765

10
Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several year

Author:Liu, Qianwei; Fang, Fang; Xue, Huiwen; Wasterlid, Tove; Smedby, Karin Ekstrom; Liu, Xinyuan

Journal: BLOOD ADVANCES. 2026; Vol. 10, Issue 4, pp. 1293-1300. DOI: 10.1182/bloodadvances.2024015776


在线咨询

Blood Advances

国际简称:BLOOD ADV参考译名:血液进展

年发文量:494 CiteScore:11.8 是否预警:否 Gold OA文章占比:99.75% 研究类文章占比:94.94%

杂志社联系方式:2021 L ST NW, SUITE 900, WASHINGTON, USA, DC, 20036

Blood Advances